1. Home >
  2. M&A >
  3. Merger >
  4. United States >
  5. California >
  6. Roche Acquires Poseida Therapeutics

M&A Deal Summary

Roche Acquires Poseida Therapeutics

On November 26, 2024, Roche acquired life science company Poseida Therapeutics for 1.0B USD

Acquisition Highlights
  • This is Roche’s 30th transaction in the Life Science sector.
  • This is Roche’s 12th largest (disclosed) transaction.
  • This is Roche’s 29th transaction in the United States.
  • This is Roche’s 15th transaction in California.

M&A Deal Summary
Date 2024-11-26
Target Poseida Therapeutics
Sector Life Science
Buyer(s) Roche
Deal Type Merger
Deal Value 1.0B USD
Advisor(s) Centerview Partners (Financial)
Cooley (Legal)

Target

Poseida Therapeutics

San Diego, California, United States
Poseida Therapeutics is a therapeutics-focused biotechnology company using best-in-class genome engineering technologies to develop novel, life-saving treatments, including gene therapies for orphan liver diseases and immuno-oncology therapeutics for several types of cancer. Poseida Therapeutics was founded in 2014 and is based in San Diego, California.

Search 214,981 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Roche

Basel, Switzerland
Category Company
Founded 1896
Sector Life Science
Employees100,920
Revenue 62.4B CHF (2024)
DESCRIPTION
Roche's corporate headquarters in Basel, Switzerland.
Roche's corporate headquarters in Basel, Switzerland.

Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. It offers diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.

DEAL STATS #
Overall 43 of 44
Sector: Life Science M&A 30 of 31
Type: Merger M&A Deals 5 of 5
State: California M&A 15 of 16
Country: United States M&A 29 of 30
Year: 2024 M&A 1 of 1
Size (of disclosed) 12 of 31
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-12-04 Carmot

Berkeley, California, United States

Carmot is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases, including obesity and diabetes. The company's expertise in metabolic biology has enabled the development of a broad pipeline of therapeutics, including three clinical candidates: CT-388 (once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist), CT-996 (once-daily oral, small molecule GLP-1 receptor agonist) and CT-868 (once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist) and other molecules in preclinical development. Carmot is based in Berkeley, California.

Buy $2.7B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2025-09-17 89bio

San Francisco, California, United States

89bio operates as a biopharmaceutical company that focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. 89bio was formed in 2018 and is based in San Francisco, California.

Buy $2.4B
Mergr

Solution for

Product

Company

Legal